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ABSTRACT:
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignant 
hematological disorder arising in the thymus from T-cell progenitors. T-ALL mainly 
affects children and young adults, and remains fatal in 20% of adolescents and 50% 
of adults, despite progress in polychemotherapy protocols. Therefore, innovative 
targeted therapies are desperately needed for patients with a dismal prognosis. 
Aberrant activation of PI3K/Akt/mTOR signaling is a common event in T-ALL patients 
and portends a poor prognosis. Preclinical studies have highlighted that modulators 
of PI3K/Akt/mTOR signaling could have a therapeutic relevance in T-ALL. However, 
the best strategy for inhibiting this highly complex signal transduction pathway is still 
unclear, as the pharmaceutical companies have disclosed an impressive array of small 
molecules targeting this signaling network at different levels. Here, we demonstrate 
that a dual PI3K/PDK1 inhibitor, NVP-BAG956, displayed the most powerful cytotoxic 
effects against T-ALL cell lines and primary patients samples, when compared with 
a pan class I PI3K inhibitor (GDC-0941), an allosteric Akt inhibitor (MK-2206), an 
mTORC1 allosteric inhibitor (RAD-001), or an ATP-competitive mTORC1/mTORC2 
inhibitor (KU-63794). Moreover, we also document that combinations of some of 
the aforementioned drugs strongly synergized against T-ALL cells at concentrations 
well below their respective IC50. This observation indicates that vertical inhibition 
at different levels of the PI3K/Akt/mTOR network could be considered as a future 
innovative strategy for treating T-ALL patients.  
INTRODUCTION 
T-cell acute lymphoblastic leukemia (T-ALL) is a 
group of neoplastic disorders, arising in the thymus, that 
affect lymphoblasts committed to the T-cell lineage [1, 
2]. T-ALL represents approximately 15% and 25% of 
pediatric and adult ALL cases, respectively, and mortality 
from T-ALL is still 20% for children and about 40-50% 
for adults [2]. For this reason, many research efforts are 
currently devoted to the development of targeted therapies 
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to limit side effects of chemotherapy and to increase 
treatment efficacy for poor prognosis patients [3]. T-ALL 
blast cells display different molecular characteristics that 
affect disease evolution and prognosis [4]. Recently, it 
has been demonstrated that the same histopathological 
phenotype could be initiated by different point mutations, 
translocations, amplifications, deletions, and epigenetic 
modulation of gene expression that may contribute to the 
development of the cancer [5]. Actually, in different and 
potentially oncogenic strategic points, mutations arise and 
Figure 1: Inhibitors of PI3K/Akt/mTOR signaling affect viability of T-ALL cell lines. MTT assays on T-ALL cell lines treated 
with GDC-0941, MK-2206, NVP-BAG956, KU-63794, RAD-001 for 24 h. The results are the mean of three different experiments ± s.d. 
Table 1: IC50s [µM] of PI3K/Akt/mTOR inhibitors tested against T-ALL cells lines. T-ALL cells 
were treated with the drugs for 24 h, then the rates of survival were evaluated by MTT assays. n.a.: IC50 
not achieved within the concentration range utilized during the present study (0.1-20 µM).
COMPOUND GDC-0941 MK-2206 NVP-BAG956 KU-63794 RAD-001
T-
A
LL
 c
el
l 
lin
es
CEM-R n.a. 6.20 0.95 10.10 5.80
CEM-S 8.20 1.40 1.14 4.20 n.a.
JURKAT 15.00 8.80 2.14 17.30 3.04
MOLT-4 2.80 1.30 0.54 3.00 0.90
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Figure 2: PI3K/Akt/mTOR signaling modulators affect cycle progression and induce apoptosis in MOLT-4 cells. (A) 
MOLT-4 cell line was treated for 24 h with increasing concentrations of GDC-0941, MK-2206, NVP-BAG956, RAD-001 and KU-63794. 
Then, cell cycle analysis was performed by flow cytometry. One representative of three separate experiments ± s.d. is shown that yielded 
similar results. CTRL: control cells. Asterisks indicate significant differences (p <0.05) relative to control cells. (B) MOLT-4 cell line was 
treated for 24 h with GDC-0941, MK-2206, NVP-BAG956, RAD-001 and KU-63794 (1 µM). Then, cells were stained with Annexin 
V-FITC/PI and analyzed by flow cytometry. One representative of three separate experiments is shown that yielded similar results. CTRL: 
control cells. 
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allow the tumor cells to support their proliferation and 
survival [6]. The PI3K/Akt/mTOR cascade is a crucial 
signal transduction pathway involved in cell growth, 
survival, and drug-resistance [7, 8]. Cancer cells, that 
escape the physiological regulation of this axis, increase 
their survival and proliferation [9]. Therefore, it is of 
great importance to study new therapeutic strategies 
to inhibit this signaling pathway. PI3K/Akt/mTOR 
constitutive activation is linked both to the pathogenesis 
and to progression of a wide variety of human cancers, 
including T-ALL [10-12]. In 50-75% of T-ALL patients, 
this pathway is constitutively active and negatively affects 
patient outcome [13]. Although several preclinical studies 
indicated that inhibition of PI3K/Akt/mTOR signaling 
could be an effective treatment for targeted therapy of 
T-ALL [13], it is still unclear which is the best target in this 
highly complex and branched signaling network. Indeed, 
pharmaceutical companies have disclosed an impressive 
array of inhibitors, targeting various components of this 
cascade [14, 15]. 
With the above in mind, we decided to undertake 
a comprehensive study where different inhibitors were 
tested under the same conditions, against T-ALL cells 
(both cell lines and primary samples from patients) 
displaying constitutive PI3K/Akt/mTOR activation. 
We analyzed the cytotoxic effects of a pan class I PI3K 
inhibitor (GDC-0941, [16]), an allosteric Akt inhibitor 
(MK-2206 [17]), a dual PI3K/PDK1 inhibitor (NVP-
BAG956, [18]), an allosteric mTOR inhibitor (RAD-001 
or Everolimus [19]), and an mTOR complex 1 (mTORC1)/
mTOR complex 2 (mTORC2) ATP-competitive inhibitor 
(KU-63794 [20]). Some of the compounds we tested, 
have been approved (RAD-001) or have entered phase I/
II clinical trials (GDC-0941, MK-2206) for solid tumor 
treatment. Here, we demonstrated that some of these drugs 
had a strong cytotoxic activity against T-ALL cell lines 
and primary cells. NVP-BAG956 displayed the highest 
efficacy. The combined use of some of these compounds 
was highly synergistic. We also documented the cytotoxic 
effects of NVP-BAG956 and MK-2006 against a T-ALL 
cell subpopulation (CD34+/CD7-/CD4-) enriched for 
cancer stem cells (or leukemia initiating cells, LICs). The 
use of compounds able to eradicate LICs could reduce the 
percentage of treatment failures and decrease the relapse 
risk of T-ALL patients.
RESULTS
Inhibitors of PI3K/Akt/mTOR signaling are 
cytotoxic to T-ALL cell lines
The effects of inhibitors of PI3K/Akt/mTOR 
signaling on T-ALL cells were first analyzed by treating 
the cells with increasing concentrations of the drugs for 24 
h and then evaluating the rates of survival by MTT assays. 
It is worth recalling here that all the T-ALL cell lines 
we used are PTEN-negative and display a defective p53 
pathway [21]. Moreover,  Jurkat cells do not express the 
inositol 5-phosphatase SHIP1 [22]. Both PTEN and SHIP1 
are negative regulators of PI3K/Akt/mTOR signaling [23]. 
GDC-0941, a pan class I PI3K inhibitor, was 
effective on MOLT-4 cells (IC50= 2.8 µM), whereas 
CEM-S, and Jurkat cells displayed a much lower 
sensitivity (IC50 > 8.2 µM) (Table 1 and Fig. 1). CEM-R 
cells, that overexpress the ABCB1 drug transporter (also 
referred to as 170-KDa P-glycoprotein, one of major 
determinants of drug-resistance [24]), were resistant to 
Figure 3: Effect of the signal transduction modulators on the phosphorylation status of PI3K/Akt/mTOR signaling 
components. MOLT-4, Jurkat, CEM-R, and CEM-S cell lines were treated with increasing concentrations of GDC-0941, MK-2206, 
NVP-BAG956, RAD-001, and KU-63794 for 24 h. Then, cells were collected, lysed, and analyzed by western blotting. An antibody to 
β-actin documented equal lane loading (50 µg of protein/lane).
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GDC-0941. MK-2206 (an allosteric Akt inhibitor) was 
effective in both CEM-S and MOLT-4 cells (IC50 around 
1.3-1.4 µM) whereas its cytotoxic effects on CEM-R 
and Jurkat cells were much lower (Table 1 and Fig. 1). 
Overall, NVP-BAG956, a dual PI3K/PDK1 inhibitor, 
was more effective than any other inhibitors tested. Most 
cell lines displayed an IC50 for NVP-BAG956 near to or 
lower than 1 µM, with the MOLT-4 cell line having the 
highest sensitivity to the drug (IC50= 500 nM) (Table 1 and 
Fig. 1). The allosteric mTORC1 inhibitor, RAD-001, was 
maximally efficacious on MOLT-4 (IC50= 900 nM), while 
Jurkat and CEM-R cells were less sensitive. The IC50 
for RAD-001 on CEM-S cells was not achieved within 
the concentration range we utilized (Table 1 and Fig. 1). 
Finally, KU-63794, a dual ATP-competitive mTORC1/
mTORC2 inhibitor, was effective on MOLT-4 and CEM-S 
cells (IC50= 3-4 µM), while Jurkat and CEM-R cells 
displayed a much higher IC50 (Table 1 and Fig. 1). 
Inhibitors of PI3K/Akt/mTOR signaling block 
cells in the G0/G1 phase of the cell cycle and 
induce apoptosis
To determine whether treatment of T-ALL cell lines 
with inhibitors of PI3K/Akt/mTOR signaling could affect 
cell cycle progression, MOLT-4 cells were incubated for 
24 h with increasing concentrations of the drugs (0.1-
1 µM) and the cell cycle was studied by means of flow 
cytometric analysis of propidium iodide (PI) -stained 
samples. All the drugs induced a statistically significant 
G0/G1 block and a concomitant decrease in both S and 
G2/M phases of the cell cycle  (Fig. 2A). The induction of 
apoptosis was investigated by means of Annexin V-FITC/
PI staining and flow cytometric analysis in MOLT-4 cells. 
The drugs that most potently induced apoptosis were MK-
2206 and KU-63794 (Fig. 2B). 
Effects of the inhibitors on PI3K/Akt/mTOR 
signaling in T-ALL cell lines
Western blot analysis demonstrated a concentration-
dependent decrease in Ser 473 p-Akt, indicative of 
mTORC2 inhibition [25], after 24 h of treatment with 
all the PI3K/Akt/mTOR inhibitors, in all the cell lines 
analyzed (Fig. 3). Total Akt levels were unaffected 
by the drugs, except for NVP-BAG956 at the highest 
concentration employed. S6 ribosomal protein (S6RP), an 
mTORC1 downstream substrate [26], was also efficiently 
dephosphorylated by the inhibitors (Fig. 3). A time-
dependent study was also performed and documented 
Figure 4: Time course of the phosphorylation status of PI3K/Akt/mTOR signaling components in response to drug 
treatment. MOLT-4 (A) and CEM-R (B) cell lines were treated with 1 µM of GDC-0941, MK-2206, or NVP-BAG956, for 6, 16, 24 
and 48 h, then they were collected, lysed, and analyzed by western blot. An antibody to β-actin documented equal lane loading (50 µg of 
protein/lane).
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that, in MOLT-4 and in CEM-R cell lines, GDC-0941, 
MK-2206, and NVP-BAG956 (1 µM) dephosphorylated 
Ser 473 p-Akt, p-S6RP, and p-4E-BP1 (another mTORC1 
downstream target [27]) already after 6 h of treatment 
(Fig. 4).
Inhibitors of PI3K/Akt/mTOR signaling synergize 
together 
Then, it was investigated whether GDC-0941, MK-
2206, NVP-BAG956, KU-63794, and RAD-001 could 
mutually synergize in T-ALL cells. CEM-S cells were 
incubated for 24 h with either one drug alone or with a 
combination of two drugs at an equal ratio. MTT assays 
were then performed. The less effective combinations 
were those consisting of GDC-0941/KU-63794, GDC-
0941/MK-2206, GDC-0941/NVP-BAG965, GDC0941/
RAD-001, MK-2206/NVP-BAG965. Indeed, with these 
combined treatments, an antagonism was frequently 
detected, and, when a synergism was observed, the 
combination index (CI) was usually not lower than 0.6, 
indicating a weak synergism (data not shown and Fig. 5A). 
In contrast, a strong synergism (CI <0.3) was 
observed with MK-2206/RAD-001, MK-2206/KU-
63794, NVP-BAG956/KU-63794, NVP-BAG956/RAD-
001, and RAD-001/KU-63794 combinations  (Fig. 5A). 
Notably, result analysis documented the existence of 
strong synergisms at drug concentrations well below the 
respective IC50 for these drugs in CEM-S cells. 
Furthermore, we analyzed the effects of the RAD-
001/KU-63794 combination on cell cycle progression, as 
these two drugs strongly synergized at 1 µM (CI<0.15). 
It is worth emphasizing here that in CEM-S cells the 
IC50 for KU-63794 was 4.2 µM, whereas the IC50 for 
RAD-001 was not achieved (see Table 1). After 24 h of 
administration of the drug combination, it was clearly 
noticeable a marked increase in the percentage of G0/G1 
cells and a concomitant decrease in S and G2/M cells when 
compared with treatment with either drug alone (Fig. 5B). 
Inhibitors of PI3K/Akt/mTOR signaling have 
cytotoxic effects on T-ALL patient samples
To better evaluate the effectiveness of PI3K/
Akt/mTOR inhbitors as potential therapeutic agents in 
T-ALL, we examined 6 pediatric T-ALL patient samples, 
isolated from bone marrow or peripheral blood and 
characterized by constitutive activation of the pathway. 
Figure 5: Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in CEM-S cells. (A) CEM-S cell lines were 
treated for 24 h with either drug alone or the combination of the two drugs at a fixed ratio. The combination index (CI) value for each data 
point was calculated with the appropriate software for dose effect analysis (CalcuSyn). Results are the mean of three different experiments 
± s.d. (B) CEM-S cell line was treated for 24 h either RAD-001or KU-63794 alone,  and with a combination of the two drugs at the same 
concentration (1 µM). Then, cell cycle analysis was performed by flow cytometry. One representative of three separate experiments is 
shown that yielded similar results. CTRL: control cells.
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The effects of PI3K/Akt/mTOR signaling inhibitors on 
T-ALL lymphoblast samples, grown in the presence of 
interleukin-7 (IL-7), were evaluated by first treating the 
cells with increasing concentrations of the drugs and 
then analyzing the rates of survival by MTT assays. Four 
representative patients are presented in Fig. 6A. A marked 
reduction of cell viability at 96 h was detected. The two 
most powerful drugs were NVP-BAG956 (IC50  about 0.14 
µM) and MK-2206 (IC50 about 0.44 µM). 
For this reason, we performed western blot analysis 
on patient samples treated for 48 h with MK-2206 and 
NVP-BAG956, which demonstrated a decrease in the 
levels of Thr 308 p-Akt, Ser 473 p-Akt, p-4E-BP1, and 
p-S6RP, while their total levels of expression did not 
change.
PI3K/Akt/mTOR signaling inhibitors activate 
caspase-3 and induce apoptosis in T-ALL 
lymphoblasts
T-ALL lymphoblasts samples were analyzed to 
evaluate the levels of cleaved caspase-3 and the induction 
of apoptosis in response to treatment with MK-2206 or 
Figure 6: Inhibitors of PI3K/Akt/mTOR signaling are cytotoxic to T-ALL primary cells. (A) MTT assay on four representative 
patient samples treated for 96 h with 10 ng/ml interleukin-7 and increasing concentrations of GDC-0941, MK-2206, NVP-BAG956, KU-
63794, or RAD-001. Results are the mean of at three different experiments ± s.d. (B) Western blot analysis of a representative patient 
samples treated for 48 h with 2 µM  MK-2206 or NVP-BAG956. Fifty µg of each lysate were electrophoresed on SDS-PAGE, transferred 
to a nitrocellulose membrane and probed with the appropriate antibodies. One representative of two different experiments is shown. CTRL: 
control cells.
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NVP-BAG956. Flow cytometric analysis documented 
that the drugs caused an increase in cleaved caspase-3 
and an induction of apoptosis, as documented by Annexin 
V-FITC/PI staining (Fig. 7A).
Inhibitors of PI3K/Akt/mTOR signaling induce 
apoptosis in the CD34+/CD7-/CD4- subset of 
patient lymphoblasts
Finally, using quadruple staining and flow 
cytometric analysis, we investigated whether MK-2206 
and NVP-BAG956 could induce apoptosis in a T-ALL 
patient lymphoblast subset (CD34+/CD7-/CD4-), which is 
enriched in putative LICs [28]. After electronic gating on 
the CD7-/CD4- lymphoblast subset, cells were analyzed 
for CD34 expression and positivity to Annexin V staining. 
After 48 h of treatment, the drugs markedly induced 
apoptosis in the CD34+/CD7-/CD4- subpopulation (Fig. 
7B). NVP-BAG956 was slightly more powerful than MK-
2206, even when used at an equimolar concentration.
DISCUSSION 
PI3K/Akt/mTOR signaling dysregulation play 
a key role in the onset of human cancers [29, 30]. 
Indeed, constitutive activation of this axis is associated 
with aberrant cell survival [15] and controls neoplastic 
motility, invasion, and metastasis [31]. Recent studies 
have suggested that this axis could be a promising target 
in T-ALL [32, 33], as in more than 70% of T-ALL patients, 
PI3K/Akt/mTOR signaling is constitutively activated and 
portends a poor prognosis [34]. In light of this, it is very 
important to develop new therapeutic strategies against 
T-ALL cells aimed to negatively modulate this signal 
cascade for improving the clinical outcome of the patients. 
Since aberrant PI3K/Akt/mTOR pathway activation 
plays a crucial role in the pathogenesis of T-ALL, the 
Figure 7: Inhibitors of PI3K/Akt/mTOR signaling induce apoptosis in T-ALL lymphoblasts and putative LICs. (A) 
Flow cytometric analysis of patient samples treated for 24 h with 2 µM MK-2206 or NVP-BAG956. Cells were stained with AlexaFluor 
488-conjugated anti-cleaved caspase-3 or with Annexin V-FITC/PI. The percentages of positive cells are indicated. The plots are 
representative of three separate experiments which were performed in duplicate. (B) Flow cytometric analysis of patient samples enriched 
for LICs, treated for 48 h with 2 µM MK-2206 or NVP-BAG956. The CD34+/CD7-/CD4- subset was stained with Annexin-FITC, to analyze 
apoptosis induction by the drugs (2 µM). In A and B one representative of two different experiments is shown. CTRL: control cells.
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aim of this research has been to test and compare the 
therapeutic potential of  selective inhibitors, such as 
GDC-0941, MK-2206, NVP-BAG956, RAD-001, and 
KU-63794. In this study, we tested these drugs either 
alone or in combination, against T-ALL cell lines and 
primary samples from T-ALL patients. The highest 
cytotoxic potential against T-ALL cell lines and patient 
lymphoblasts was displayed by NVP-BAG956, a dual 
PI3K/PDK1 inhibitor which has been shown to be 
effective against BCR-ABL- and mutant FLT3-expressing 
acute leukemia cells [18]. Subsequently, NVP-BAG956 
has been documented to affect proliferation of melanoma 
cells [35]. To our knowledge this is the first time this drug 
is used against T-ALL cells. NVP-BAG956 was mainly 
cytostatic in T-ALL cell lines and was not a strong inducer 
of apoptosis. However, it potently induced apoptosis 
in T-ALL primary cells, including a cell subset that is 
enriched in putative LICs. GDC-0941 is an inhibitor of 
class I PI3K that has entered clinical trials for solid tumors 
[16]. In T-ALL cell lines and patient samples, GDC-0941 
displayed a weak cytostatic effect. MOLT-4 cells were 
more sensitive to GDC-0941 than the other cell lines. The 
allosteric Akt inhibitor MK-2206 [36], that is presently 
undergoing clinical trials for the treatment of solid 
tumors [17], was more powerful than GDC-0941 in both 
T-ALL cell lines and primary samples. Apart from being 
cytostatic, MK-2206 also induced apoptosis.
Surprisingly, we found that RAD-001 (an allosteric 
mTORC1 inhibitor belonging to the rapalog class [37]) 
was more powerful than KU-63794, an ATP-competitive 
mTORC1/mTORC2 inhibitor [20], especially in MOLT-
4 cells. Indeed, ATP-competitive mTORC1/mTORC2 
inhibitors are generally considered to be more powerful 
than rapamycin and rapalogs [38]. However, RAD-001 
and KU-63794 displayed nearly similar weak potency 
against T-ALL lymphoblasts. 
An interesting observation is that RAD-001 
treatment resulted in Ser 473 p-Akt dephosphorylation 
in T-ALL cell lines. In most cancer cell types, rapalogs 
such as RAD-001, increased Akt phosphorylation 
through inhibition of a negative feed-back loop based on 
mTORC1/p70S6K/IRS1/PI3K [39]. Inhibition of such a 
negative feed-back loop up-regulates mTORC2-dependent 
phosphorylation of Akt on Ser 473 and increases cell 
survival [40]. However, the rapalog inhibitor CCI-779 has 
been reported to cause mTORC2 disassembly and Ser 473 
p-Akt dephosphorylation [41]. Thus, it may be that RAD-
001 disassembled mTORC2 complex in T-ALL cell lines. 
This finding seems also to indicate that rapamycin and 
RAD-001 effects are not superimposable, as rapamycin 
treatment of T-ALL cell lines, under the same conditions 
employed here as for RAD-001, did not result in Ser 473 
p-Akt dephosphorylation in the same T-ALL cell lines 
[21]. 
A rapidly emerging theme in targeted therapy of 
PI3K/Akt/mTOR signaling, is that combined “vertical” 
inhibition at different nodes of the cascade often leads to 
better results that the use of either single or dual inhibitors. 
However, most of the studies performed in this field so 
far took advantage of solid tumor models [42-44]. As far 
as we know, this is the first report which documented the 
superior efficacy of vertical targeting of the PI3K/Akt/
mTOR pathway in T-ALL cell lines. Previous evidence 
has demonstrated that the PI3K/Akt/mTOR network is 
characterized by multiple feed-back loops that finely act 
to regulate signal transduction [45]. Hence, the existence 
of these loops could limit the antitumor effects of PI3K/
Akt/mTOR inhibitors given in monotherapy settings, 
and explains the importance of testing the effects of 
combination treatment. Consequently, inhibiting at the 
same time at different levels and with different inhibitors 
the PI3K/Akt/mTOR pathway is a possible strategy 
to enhance their effectiveness on leukemic cells. It is 
remarkable that in T-ALL cell lines, a synergism was 
detected for drugs used at various concentrations that 
were considerably below the IC50 of the drugs when 
administered alone. The most effective drug combinations 
in T-ALL lines were those consisting of MK-2206/RAD-
001, MK-2206/KU-63794, NVP-BAG956/KU-63794, 
NVP-BAG956/RAD-001, and RAD-001/KU-63794. 
These findings could have a clinical relevance for T-ALL 
patients. Indeed, as combinations of these drugs increased 
the cytotoxicity, the use of a much lower concentration 
of the inhibitors was possible and could considerably 
attenuate the toxic side effects. Experiments are underway 
to better understand the molecular mechanisms underlying 
the increased cytotoxic effects of these combinations. 
Moreover, it is important to emphasize that, in 
T-ALL patients lymphoblasts, both MK-2206 and NVP-
BAG956 were cytotoxic to putative LICs. LICs express 
surface markers normally exhibited by stem cells and 
they are more resistant to various chemotherapies [46]. 
Strategies that eliminate these cells could have significant 
clinical implications [47, 48]. In conclusion, our results 
demonstrated that targeting PI3K/Akt/mTOR pathway at 
different levels in T-ALL cell lines resulted in an increase 
of cytotoxic effects and then at least some of tested 
inhibitors may represent promising drugs also for their 
capacity to target T-ALL LICs.
MATERIALS AND METHODS
Materials
GDC-0941 and NVP-BAG956 were purchased from 
Axon Medchem BV (Groningen, The Netherlands), while 
MK-2206, KU-63794, and RAD-001 were purchased 
from Selleck Chemicals (Houston, TX, USA). For 
western blotting, primary antibodies were bought from 
Cell Signaling Technology (Danvers, MA, USA). For 
flow cytometric analysis, AlexaFluor  488-conjugated 
antibody to cleaved caspase-3 was from Beckman Coulter 
Oncotarget 2012; 3: 811-823820www.impactjournals.com/oncotarget
(Miami, FL, USA).
Cell culture and primary samples
The T-ALL cell lines Jurkat, MOLT-4, CEM-S, 
and CEM-R (CEM VBL100, drug-resistant cells 
overexpressing the ABCB1 drug transporter [49]) 
were grown in RPMI 1640, supplemented with 10% 
fetal bovine serum (FBS), L-glutamine, and penicillin-
streptomycin (Sigma Aldrich, St Louis, MO, USA). 
Samples from T-ALL pediatric patients were obtained with 
informed consent according to institutional guidelines 
and isolated using Ficoll-Paque (Amersham Biosciences, 
Little Chalfont, UK) [50, 51] and were grown in complete 
medium [RPMI 1640 supplemented with 20% FBS, ITS 
(insulin-transferrin-sodium selenite), and amphotericin B]. 
Cell viability analysis
MTT (3-[4,5-Dimethylthythiazol-2-yl]-2,5-
Diphenyltetrazolium Bromide) assays were performed 
to assess the sensitivity of cells to drugs, as previously 
described [52]. In particular, T-ALL patient lymphoblasts 
(2 x 106 cells/ml) were cultured in triplicate in flat-
bottomed 96-well plates at 37°C with 5% CO2. 
Cultures were carried out for 96 h in complete medium 
supplemented with 10 ng/ml IL-7. Results were 
statistically analyzed by GraphPadPrism Software 
(GraphPad Software Inc., San Diego, CA, USA).
Cell cycle analysis
Flow cytometric analysis was performed using a 
PI/RNase A staining according to standard procedures, 
as described previously [53, 54]. Samples were analyzed 
on a FC500 flow cytometer (Beckman Coulter) with the 
appropriate software (CXP, Beckman Coulter). 
Flow cytometric analysis of Annexin V-FITC in T-ALL 
cell lines and patient samples 
After in vitro drug treatment, T-ALL cell lines and 
patient lymphoblasts were washed twice in PBS, labeled 
with Annexin V-FITC in binding buffer, stained with PI, 
and then analyzed by flow cytometry on an FC500 flow 
cytometer [55]. 
Western blot analysis 
This was performed by standard methods, as 
previously reported [56]. Analysis with an antibody to 
β-actin demonstrated equal protein loading.
Combined drug effect analysis 
The combination effect and potential synergy 
were evaluated from quantitative analysis of dose-effect 
relationships, as described previously [57]. For each 
combination experiment, a CI number was calculated 
using the CalcuSyn software (Biosoft, Cambridge, UK). 
This method of analysis generally defines CI values of 0.9 
to 1.1 as additive, 0.3 to 0.9 as synergistic, and <0.3 as 
strongly synergistic, whereas values >1.1 are considered 
antagonistic. 
Flow cytometric analysis of cleaved caspase-3 levels in 
T-ALL patient samples 
After in vitro treatment, T-ALL lymphoblasts 
were fixed in Reagent 1 of the Intraprep Kit (Beckman 
Coulter) and permeabilized with saponin-based Reagent 
2, as reported elsewhere [49]. Cells were incubated with 
an anti-cleaved caspase-3 primary antibody conjugated 
to AlexaFluor 488. A rabbit IgG conjugated to 
AlexaFluor 488 was used as an irrelevant antibody. 
Cells were analyzed on a FC500 flow cytometer [49].
Flow cytometric analysis of putative T-ALL LIC
This was performed essentially as previously 
reported [49]. To detect apoptotic cells, samples were 
incubated with Annexin V-FITC. Samples were analyzed 
on a Navios flow cytometer (Beckman Coulter) equipped 
with Kaluza software (Beckman Coulter). 
Statistical evaluation 
The data are presented as mean values from three 
separate experiments ± s.d. Data were statistically 
analyzed by a Dunnet test after one-way analysis of 
variance (ANOVA) at a level of significance of p < 0.05 
vs. control samples. 
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